Obalon Announces Issuance of First U.S. Patent Covering Its Proprietary Navigation System
June 04 2019 - 8:30AM
Obalon Therapeutics, Inc. (NASDAQ:OBLN), a vertically integrated
medical technology company with the first and only FDA-approved
swallowable, gas-filled intragastric balloon system for the
treatment of obesity, announces the issuance of U.S. Patent
No. 10,264,995, entitled SYSTEMS AND METHODS FOR LOCATING AND/OR
CHARACTERIZING INTRAGASTRIC DEVICES.
The first of its kind Obalon Navigation System provides the
treating physician with the ability to place the Obalon Balloon
without having to incur the costs and inconvenience of utilizing
x-ray imaging. The Obalon Navigation System is portable, easy to
use, non-invasive, radiation free, and provides dynamic tracking of
the Obalon Balloon during placement.
The newly issued patent covers multiple aspects of the Obalon
Navigation System, including dynamic tracking using internal and
external sensors with an external electromagnetic field.
“We believe this patent provides protection against anyone else
entering the market, either with a gas-filled or liquid-filled
balloon, that wants to use a similar system to avoid the extra
costs and considerable logistics of using x-ray during placement,”
said Mark Brister, Obalon’s Chief Technology Officer.
Obalon now has 20 patents issued in the U.S. and 31 patents
issued internationally that cover the Obalon Balloon System, with
25 and 55 pending patent applications in the U.S. and in
international territories, respectively.
“We have used Obalons’ prior generation EzFill balloon, liquid
filled balloons, and now the Obalon Navigation System,“ said Dr.
Jeremias C. Tan, MD, Health and Wellness Services, Medical Director
Gastroenterology Associates of Northern Virginia. “On average,
Navigation balloon placements take about 15 minutes in our office.
Automated inflation improves patient satisfaction and helps make
placement of Navigation intragastric balloons more convenient for
both the patient and the doctor. The Obalon Balloon System is a
safe, effective and efficient solution for individuals with a BMI
between 30 to 40 kg/m2 who are ready to lose weight and improve
their overall health.”
About Obalon Therapeutics, Inc. Obalon
Therapeutics, Inc. (NASDAQ:OBLN) is a San Diego-based company
focused on developing and commercializing novel technologies for
weight loss. For more information, please
visit www.obalon.com.
Forward-Looking Statements
To the extent that statements contained in this
press release are not descriptions of historical facts regarding
Obalon Therapeutics, they are forward-looking statements reflecting
the current beliefs and expectations of management made pursuant to
the safe harbor of the Private Securities Reform Act of 1995. Such
forward-looking statements involve substantial risks and
uncertainties that could cause Obalon Therapeutics' future results,
performance or achievements to differ significantly from those
expressed or implied by the forward-looking statements. Obalon
Therapeutics undertakes no obligation to update or revise any
forward-looking statements. For a description of the risks and
uncertainties that could cause actual results to differ from those
expressed in these forward-looking statements, as well as risks
relating to Obalon Therapeutics' business in general, please refer
to Obalon Therapeutics’ annual report on Form 10-K filed with the
Securities and Exchange Commission on February 22, 2019, Form 10-Q
filed with the Securities and Exchange Commission on May 10, 2019,
and its future periodic reports filed with the Securities and
Exchange Commission.
For Obalon Therapeutics, Inc.Investor Contact:
William Plovanic President & Chief Financial Officer Obalon
Therapeutics, Inc. Office: +1 760 607 5103 wplovanic@obalon.com
Obalon Therapeutics (NASDAQ:OBLN)
Historical Stock Chart
From Mar 2024 to Apr 2024
Obalon Therapeutics (NASDAQ:OBLN)
Historical Stock Chart
From Apr 2023 to Apr 2024